Aligned Genetics

Aligned Genetics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Aligned Genetics (238120.KQ) as of Oct 30, 2026 is -319.46 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 66.02 % — a change of -583.90% (lower).

FCF Conversion

-319.46 %

YoY

-583.90%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Aligned Genetics is 2025 -319.46 % . FCF Conversion Rate (FCF/EBITDA) of Aligned Genetics was 2024 66.02 % . It decreases by -583.90% lower compared to the previous year.

The Aligned Genetics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
123.50 KRW
Jan 1, 2019
340.65 KRW
Jan 1, 2020
-12.98 KRW
Jan 1, 2021
-57.23 KRW
Jan 1, 2022
9.47 KRW
Jan 1, 2023
60.82 KRW
Jan 1, 2024
66.02 KRW
Jan 1, 2025
-319.46 KRW
The Aligned Genetics FCF Conversion history
YEARFCF ConversionYoY
-319.46 %-583.90%
66.02 %+8.54%
60.82 %+542.05%
9.47 %-116.55%
-57.23 %+341.01%
-12.98 %-103.81%
340.65 %+175.84%
123.50 %+68.97%
73.09 %-43.30%
128.89 %-56.62%
297.13 %+31.29%
226.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Aligned Genetics Stock analysis

What does Aligned Genetics do? Aligned Genetics Inc, based in Anyang, South Korea, operates in the Health Care sector within the Life Sciences Tools & Services industry. The company commercializes innovative products for life science research, including automated cell counters like LUNA and LUNA-FL, tissue clearing systems such as X-CLARITY, and digital cell imaging systems like iRiS. Listed on November 3, 2016, it serves the global research community with advanced laboratory solutions. Aligned Genetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aligned Genetics stock

FCF Conversion Rate (FCF/EBITDA) of Aligned Genetics is -319.46 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Aligned Genetics changed from 66.02 % to -319.46 %, representing a -583.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Aligned Genetics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Aligned Genetics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Aligned Genetics

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Aligned Genetics